JP2005523239A - Suppression of exoprotein production using aromatic compounds - Google Patents

Abstract

Absorbent and non-absorbent articles are disclosed. The article includes an amount of an aromatic inhibitor compound effective to inhibit exoprotein production from Gram positive bacteria. The aromatic suppression compound of the present invention has the general formula (I), wherein R ¹ is H, (a), —OR ⁵ , —R ⁶ C (O) H, —R ⁶ OH, —R Selected from the group consisting of ⁶ COOH, —OR ⁶ OH, —OR ⁶ COOH, —C (O) NH ₂ , formula (1) and NH ₂ and salts thereof, R ⁵ is monovalent saturated or unsaturated An aliphatic hydrocarbyl moiety, R ⁶ is a divalent saturated or unsaturated aliphatic hydrocarbyl moiety, R ⁷ is a trivalent saturated or unsaturated aliphatic hydrocarbyl moiety, and R ⁸ is mediated by a heteroatom A mono-substituted or unsubstituted saturated or unsaturated aliphatic hydrocarbyl moiety that may or may not be present, wherein R ² , R ³ and R ⁴ consist of H, OH, COOH, and —C (O) R ^9. independently is selected from the group, R ⁹ is Ah hydrogen or monovalent saturated or unsaturated aliphatic hydrocarbyl moiety .

Description

Detailed Description of the Invention

(Technical field)
The present invention relates to the suppression of exoprotein production associated with absorbent articles such as menstrual tampons, or non-absorbable substrates or articles. More specifically, the present invention relates to the incorporation of certain aromatic compositions into absorbent articles or non-absorbent substrates and the effects of these compounds on gram positive bacteria. The present invention also relates to a method using an aromatic composition.

(Background technology)
Disposable absorbent devices such as menstrual tampons for absorbing human emissions are widely used. These disposable devices typically have an absorbent compact formed into the desired shape typically determined by the intended consumer use. In the field of menstrual tampons, the device is intended to be inserted into a body cavity to absorb fluids that are typically drained during a woman's menstrual period.
In the female body, there are complex processes that maintain the vagina and its physiologically related areas in a healthy state. In women between menopause and menopause, the normal vagina provides an ecosystem for various microorganisms. Bacteria are the overwhelming majority of microorganisms present in the vagina, and many women have about 10 ⁹ bacteria per gram of vaginal fluid. The vaginal flora consists of aerobic and anaerobic bacteria. More commonly detected bacteria are Lactobacillus, Corynebacterium, Vaginal Gardnerella, Staphylococcus, Peptococcus, aerobic and anaerobic Streptococcus, and bacterial-like species. Other microorganisms that are occasionally detected from the vagina include yeast (Candida albicans), protozoan subfamily (vaginal trichomonas), mycoplasma (mycoplasma hominis), chlamydia (trachoma chlamydia), and viruses (herpes simplex) It is. These latter organisms are generally associated with vaginitis or sexually transmitted diseases, but may be present in small numbers without causing symptoms.

Physiological, social and idiosyncratic factors affect the number and species of bacteria present in the vagina. Physiological factors include age, menstrual cycle days, and pregnancy. For example, the vaginal flora present in the vagina throughout the menstrual cycle can include lactobacilli, corynebacteria, and mycoplasma. Social and idiosyncratic factors include contraceptive methods, sexual activity, systemic diseases (eg, diabetes) and drugs.
Bacterial proteins and metabolites produced in the vagina can affect other microorganisms and hosts. For example, the vagina during the menstrual cycle is weakly acidic with a pH ranging from about 3.8 to about 4.5. This pH range is generally considered the most suitable condition for maintaining normal bacterial flora. At this pH, the vagina normally harbors a number of microbial species in a balanced ecosystem, which play a beneficial role in providing protection and resistance to infection, and the vagina is staphylococcus aureus (S. cerevisiae). certain bacteria such as aureus) are not settled. When the pH is low, Lactobacillus grows and these produce acidic products. Vaginal microbes can also produce antibacterial compounds and bactericides such as hydrogen peroxide directed against other bacterial species. An example is a product lactosine, such as lactobacilli bacteriocin directed against other lactobacilli species.

Some microbial products produced in the vagina can adversely affect a human host. For example, S.M. Aureus may produce and excrete in its habitat various exoproteins, including enterotoxin of the toxic shock syndrome Toxin-1 (TSST-1), and enzymes such as proteases and lipases. When absorbed into the host's bloodstream, TSST-1 can cause toxic shock syndrome (TSS) in non-immunized individuals.
S. Aureus is found in the vagina of approximately 16% of healthy women of menstrual age. Approximately 25% of S. cerevisiae detected from the vagina. aureus appears to produce TSST-1. TSST-1 and some of the staphylococcal enterotoxins have been identified as causing TSS in humans.

Symptoms of toxic shock syndrome generally include a rapid drop in blood pressure following fever, diarrhea, vomiting, and a rash. Multiple organ damage occurs in approximately 6% of people with this disease. S. Aureus does not cause toxic shock syndrome due to microbes entering the vaginal cavity. S. Instead of growing and doubling, aureus may produce TSST-1. Only after entering the bloodstream, TSST-1 toxin acts systemically and causes symptoms due to toxic shock syndrome.
The menstrual fluid has a pH of about 7.3. During the menstrual period, the vaginal pH moves in a neutral direction and may become weakly alkaline. This change gives microorganisms whose growth is inhibited by an acidic environment to proliferate. For example, S.M. Aureus is detected more frequently from menstrual vaginal swabs than from swabs collected during the menstrual period.

S. If the aureus is present in a region of the human body such as the vagina where a normal microbial population resides, it does not detract from the members of the normal flora required for a healthy vagina. Eradication of Aureus bacteria may be difficult. Typically, S.M. Antibiotics that kill Aureus are S. aureus. If not all of the aureus is killed, their effects on normal vaginal flora and their tendency to stimulate the production of their toxins are not an option for use in menstrual products. One alternative to eradication is technology that is designed to stop or substantially reduce the ability of bacteria to produce toxins.
Does the incorporation of one or more biostatic compounds, bactericidal compounds, and / or detoxified compounds into the tampon cotton removal reduce pathogenic microorganisms and the toxic shock syndrome that occurs during menstruation? Or many attempts have been made to eliminate it. For example, L-ascorbic acid has been added to menstrual tampons to detoxify toxins found in the vagina. Others incorporate monoesters and diesters of aliphatic polyhydric alcohols such as glycerol monolaurate as bactericidal compounds (see, eg, US Pat. No. 5,679,369). Still others incorporate other nonionic surfactants such as alkyl ethers, alkylamines and alkylamides as detoxifying compounds (US Pat. Nos. 5,685,872, 5,618,554). No. and 5,612,045).

  Despite the aforementioned techniques, an enzyme lipase that effectively inhibits the production of exoproteins such as TSST-1 from Gram-positive bacteria and can adversely affect efficacy and also be present in the vagina There continues to be a need for compounds that remain active in the presence of esterases. Furthermore, it is desirable that detoxifying compounds useful for inhibiting exoprotein production do not substantially harm the normal bacterial flora found in the vaginal area. It is further desirable that such detoxifying compounds be coated on absorbent articles or non-absorbent substrates or otherwise incorporated prior to use.

をもち、式中Ｒ¹は、Ｈ、

−ＯＲ⁵、−Ｒ⁶Ｃ（Ｏ）Ｈ、−Ｒ⁶ＯＨ、−Ｒ⁶ＣＯＯＨ、−ＯＲ⁶ＯＨ、−ＯＲ⁶ＣＯＯＨ、−Ｃ（Ｏ）ＮＨ₂、

及びＮＨ₂並びにそれらの塩からなる群から選択され、Ｒ⁵は、一価の飽和又は不飽和脂肪族ヒドロカルビル部分であり、Ｒ⁶は、二価の飽和又は不飽和脂肪族ヒドロカルビル部分であり、Ｒ⁷は、三価飽和又は不飽和脂肪族ヒドロカルビル部分であり、Ｒ⁸は、ヘテロ原子が介在してもしなくても良い一価置換又は非置換飽和又は不飽和脂肪族ヒドロカルビル部分であり、Ｒ²、Ｒ³及びＲ⁴は、Ｈ、ＯＨ、ＣＯＯＨ、及び−Ｃ（Ｏ）Ｒ⁹からなる群から別個に選択され、Ｒ⁹は水素又は一価飽和又は不飽和脂肪族ヒドロカルビル部分である芳香族化合物からなる１つ又はそれ以上の芳香族化合物又は組成物が、月経用タンポンのような吸収性物品か又は非吸収性基体に組み込まれたときに、グラム陽性菌のエキソプロテイン産生を実質的に抑制するという発見に基づくものである。 (Disclosure of the Invention)
The present invention has the following general formula:

Where R ¹ is H,

^{-OR 5, -R 6 C (O} ) H, -R 6 OH, -R 6 COOH, -OR 6 OH, -OR 6 COOH, -C (O) NH 2,

And NH ₂ and their salts, R ⁵ is a monovalent saturated or unsaturated aliphatic hydrocarbyl moiety, R ⁶ is a divalent saturated or unsaturated aliphatic hydrocarbyl moiety, R ⁷ is a trivalent saturated or unsaturated aliphatic hydrocarbyl moiety, R ⁸ is a monovalent substituted or unsubstituted saturated or unsaturated aliphatic hydrocarbyl moiety, which may or may not be intervened by heteroatoms, ² , R ³ and R ⁴ are independently selected from the group consisting of H, OH, COOH, and —C (O) R ⁹ , where R ⁹ is hydrogen or a fragrance that is a monovalent saturated or unsaturated aliphatic hydrocarbyl moiety. Gram-positive bacterial exoprotein production is substantially reduced when one or more aromatic compounds or compositions comprising family compounds are incorporated into absorbent articles such as menstrual tampons or non-absorbable substrates. Restrained It is based on the discovery that that.

A general object of the present invention is to provide an absorbent article that suppresses exoprotein production from Gram-positive bacteria. A more specific object of the present invention is S.I. It is to provide a menstrual tampon incorporating one or more aromatic compounds that serve to substantially suppress the production of TSST-1 and enterotoxin B by Aureus.
Another object of the present invention includes, but is not limited to, for example, S. laureth-4, PPG-5 lauryl ether, 1-0-dodecyl-rac-glycerol, disodium laureth sulfosuccinate, glycerol monolaur, which acts to substantially suppress the production of TSST-1 and enterotoxin B by Aureus Incorporates one or more aromatic compounds in combination with one or more other inhibitory ingredients such as rate, alkyl polyglycosides, polyethylene oxide (2) sorbitol ether or milles-3-myristate It is to provide menstrual tampons.
Yet another object of the present invention is for menstruation incorporating one or more compounds that suppress the production of exoprotein from Gram-positive bacteria without significantly disrupting the normal bacterial flora present in the vaginal tract. Is to provide tampons.

The present invention also relates to non-absorbable substrates or articles that inhibit exoprotein production from Gram positive bacteria. The substrate is S. It is particularly useful for inhibiting the production of TSST-1 from Aureus bacteria. Examples of suitable non-absorbable substrates into which the aromatic compounds of the present invention can be incorporated include non-absorbable incontinence devices, contraceptive barrier devices, irrigators, contraceptive sponges and tampon applicators. One particular example of a non-absorbable incontinence device is a female incontinence barrier device such as an incontinence cotton strip formed from a resilient material such as rubber. Another suitable non-absorbable substrate is an applicator used for tampons. For example, a tampon applicator can be used in the form of an aromatic compound (typically in the form of a cream, wax, gel or other suitable shape when the applicator is used to insert a tampon into a woman's vagina. Can have an aromatic compound coated on the outer surface so that it can be transferred from the applicator onto the vaginal wall.
A general object of the present invention is to provide a non-absorbable article that suppresses the production of exoprotein from Gram positive bacteria. A more specific object of the present invention is S.I. Non-absorbable incontinence device, contraceptive barrier device, contraceptive sponge, tampon applicator incorporating one or more aromatic compounds that act to substantially inhibit the production of TSST-1 and enterotoxin B by Aureus Or providing an irrigator.

Another object of the present invention includes, but is not limited to, for example, S. laureth-4, PPG-5 lauryl ether, 1-0-dodecyl-rac-glycerol, disodium laureth sulfosuccinate, glycerol monolaur, which acts to substantially suppress the production of TSST-1 and enterotoxin B by Aureus Incorporates one or more aromatic compounds in combination with one or more other inhibitory ingredients such as rate, alkyl polyglycosides, polyethylene oxide (2) sorbitol ether or milles-3-myristate It is to provide a non-absorbent substrate.
Yet another object of the present invention is non-absorption that incorporates one or more compounds that suppress the production of exoproteins from Gram-positive bacteria without significantly disrupting the balance of normal bacterial flora present in the vaginal tract. Providing a conductive substrate.
Other objects and advantages of the invention, and modifications thereof, will become apparent to those skilled in the art without departing from the inventive concept as defined in the claims.

(Best Mode for Carrying Out the Invention)
In accordance with the present invention, aromatic compounds as described herein can be absorbed like menstrual tampons to substantially inhibit the production of exoproteins such as TSST-1 from Gram-positive bacteria. It has been found that it can be used in combination with an article or a non-absorbent substrate. Further, in order to substantially suppress the production of exoprotein such as TSST-1 from Gram-positive bacteria, for example, C ₈ -C ₁₈ fatty acid is converted to aliphatic alcohol, polyalkoxylated sulfate or polyalkoxylated sulfosuccinic acid. It has also been discovered that aromatic compounds can be used in combination with other surfactants, such as compounds having ether bonds, ester bonds, amide bonds, glycoside bonds, or amine bonds linked to salts.
The present invention is described in detail herein in connection with menstrual tampons, but sanitary napkins, pantilinas, adult incontinence clothing for which exoprotein suppression from Gram-positive bacteria is beneficial, One skilled in the art will be applicable to diapers, medical bandages, and other disposable absorbent articles such as hemostatics intended to be used for medical, dental, surgical and / or nasal purposes. You will understand. The phrase “absorbent article” as used herein generally refers to a device that absorbs and contains bodily fluids, and more specifically, to absorb and contain various fluids drained from the body. Refers to a device placed on or near the skin. The term “disposable” is used herein to refer to an absorbent article that is once used and then laundered or reconstituted as an absorbent article, ie, not intended to be reused. It is done. Examples of such disposable absorbent articles include, but are not limited to, healthcare related products including bandages and antithrombotics intended to be used for medical, dental, surgical and / or nasal purposes, women Hygiene products (eg sanitary napkins, pantilinas, menstrual tampons), personal care absorbent products such as diapers, training pants, incontinence products, etc., in which exoproteins from gram-positive bacteria It is beneficial to suppress production.

The invention is also described in detail herein in the context of various nonabsorbable substrates or products such as nonabsorbable incontinence devices, contraceptive barrier devices, contraceptive sponges, tampon applicators and irrigators. However, one of ordinary skill in the art will appreciate that it is applicable to other non-absorbable articles, devices and / or products that would benefit from suppression of exoproteins from Gram positive bacteria. As used herein, the phrase “non-absorbent article” generally refers to a substrate or device that includes an outer layer formed from a substantially hydrophobic material that repels fluid, such as menstruation, blood products, and the like. That means. Suitable materials for the construction of the non-absorbent article of the present invention include, for example, rubber, plastic and cardboard.
Menstrual tampons suitable for use in the present invention are typically made from absorbent fibers comprising natural and synthetic fibers that are compressed and sized into a single piece that can be easily inserted into the vaginal cavity. . Suitable fibers include, for example, cellulose fibers such as cotton and rayon. The fibers can be 100% cotton, 100% rayon, a blend of cotton and rayon, or other materials known to be suitable for use in tampons.
Menstrual tampons are generally made in an elongated cylindrical shape so that they can have a body of material large enough to provide the required absorption capacity, but may be made in various shapes . Tampons are currently widely preferred compression type, but may or may not be compressed. The tampon may or may not have a suitable cover or wrap, and can be made from a variety of fiber blends including both absorbent and non-absorbable fibers. Suitable methods and materials for the manufacture of tampon are well known to those skilled in the art.

ここでＲ¹は、Ｈ、

−ＯＲ⁵、−Ｒ⁶Ｃ（Ｏ）Ｈ、−Ｒ⁶ＯＨ、−Ｒ⁶ＣＯＯＨ、−ＯＲ⁶ＯＨ、−ＯＲ⁶ＣＯＯＨ、−Ｃ（Ｏ）ＮＨ₂、

及びＮＨ₂並びにそれらの塩からなる群から選択され、Ｒ⁵は、一価の飽和又は不飽和脂肪族ヒドロカルビル部分であり、Ｒ⁶は、二価の飽和又は不飽和脂肪族ヒドロカルビル部分であり、Ｒ⁷は、三価飽和又は不飽和脂肪族ヒドロカルビル部分であり、Ｒ⁸は、ヘテロ原子が介在してもしなくても良い一価置換又は非置換飽和又は不飽和脂肪族ヒドロカルビル部分であり、Ｒ²、Ｒ³及びＲ⁴は、Ｈ、ＯＨ、ＣＯＯＨ、及び−Ｃ（Ｏ）Ｒ⁹からなる群から別個に選択され、Ｒ⁹は水素又は一価飽和又は不飽和脂肪族ヒドロカルビル部分である。 Certain aromatic compounds produce exoproteins by Gram-positive bacteria, specifically S. cerevisiae. It has been found that the production of TSST-1 and enterotoxin B from Aureus bacteria can be substantially suppressed. Aromatic compounds useful in the present invention have the following general chemical structure:

Where R ¹ is H,

^{-OR 5, -R 6 C (O} ) H, -R 6 OH, -R 6 COOH, -OR 6 OH, -OR 6 COOH, -C (O) NH 2,

And NH ₂ and their salts, R ⁵ is a monovalent saturated or unsaturated aliphatic hydrocarbyl moiety, R ⁶ is a divalent saturated or unsaturated aliphatic hydrocarbyl moiety, R ⁷ is a trivalent saturated or unsaturated aliphatic hydrocarbyl moiety, R ⁸ is a monovalent substituted or unsubstituted saturated or unsaturated aliphatic hydrocarbyl moiety, which may or may not be intervened by heteroatoms, ² , R ³ and R ⁴ are independently selected from the group consisting of H, OH, COOH, and —C (O) R ⁹ , where R ⁹ is hydrogen or a monovalent saturated or unsaturated aliphatic hydrocarbyl moiety.

The hydrocarbyl moieties described herein include both linear and branched hydrocarbyl moieties, which may or may not be substituted and / or intervened with heteroatoms. Desirably, the aromatic compound used in the present invention comprises at least one OH and / or COOH group. The OH and / or COOH groups can be bonded to the aromatic structure or can be bonded to an atom that may or may not be directly bonded to the aromatic structure. R ⁵ is desirably a monovalent saturated aliphatic hydrocarbyl moiety having from 1 to about 15 carbon atoms, preferably from 1 to about 14 carbon atoms. R ⁶ is desirably a divalent saturated or unsaturated aliphatic hydrocarbyl moiety having from 1 to about 15 carbon atoms, preferably from 1 to about 14 carbon atoms. R ⁷ is a trivalent saturated or unsaturated aliphatic hydrocarbyl moiety having from 1 to about 15 carbon atoms, preferably from 1 to about 10 carbon atoms, more preferably from 1 to about 4 carbon atoms. It is desirable that Heteroatoms that can intervene in the hydrocarbyl moiety include, for example, oxygen and sulfur.

Preferred aromatic compounds of the present invention are 2-phenylethanol, benzyl alcohol, trans-cinnamic acid, 4-hydroxybenzoic acid, methyl ester, 2-hydroxybenzoic acid, 2-hydroxybenzamide, acetyltyrosine, 3,4,5. -Trihydroxybenzoic acid, lauryl 3,4,5-trihydroxybenzoate, phenoxyethanol, 4-hydroxy-3-methoxybenzoic acid, p-aminobenzoic acid, and 4-acetamidophenol.
According to the present invention, the absorbent article or non-absorbent substrate containing an aromatic compound is an S.D. Contains an effective amount of an inhibitory aromatic compound that substantially inhibits the production of TSST- when exposed to aureus bacteria. S. Several methods are known in the art to test the effectiveness of potential inhibitors for the suppression of TSST-1 production in the presence of Aureus. One such preferred method is shown in Example 1 shown below. When tested according to the test methods set forth herein, the suppressed aromatic compound has an absorbent article S.I. When exposed to aureus, TSST-1 production is preferably at least about 40%, more preferably 50%, even more preferably 60%, even more preferably 70%, even more preferably 80%, Even more preferably, it is reduced by 90%, even more preferably by 95%.

When the aromatic compound is configured as a composition containing a pharmaceutically acceptable carrier, the composition is typically at least about 0.01% (volume / volume), desirably at least about 0. Contains .04% (volume / volume) aromatics (based on the total volume of the composition). Generally, the composition contains no more than about 1.0% (volume / volume) aromatics. One skilled in the art will appreciate that the concentration of the aromatic compound will vary depending on the selected compound and the other components of the formulation. A particularly suitable composition for use in vaginal irrigation fluid applications can contain at least about 0.20 mmol / liter, desirably no more than about 50 mmol / liter. Desirably, the vaginal wash composition contains from about 0.3 millimoles / liter to about 30 millimoles / liter aromatic compound, or from about 1 millimoles / liter to about 15 millimoles / liter aromatic compound.
The aromatic compounds of the present invention can contain other additives as appropriate for the desired result, so long as the additive does not have a noticeable adverse effect on the activity of the aromatic compound. Examples of such additives include conventional surfactants such as ethoxylated hydrocarbons or surfactants, or co-wetting aids such as low molecular weight alcohols.

As will be appreciated by those skilled in the art, many types of substrates, including non-woven materials such as spunbonds, meltblowns, carded webs and others, as well as woven webs, as well as films, etc., can be used as perfumes. Can be treated with a family composition. Those skilled in the art will also appreciate that certain aromatic compounds can be used as internal additives or added to the polymer directly in molten form or in concentrated form. After the fibers are formed, these additives can migrate to the fiber surface and have the desired effect. The internal addition of such additives is disclosed in US Pat. No. 5,540,979, incorporated herein by reference.
An effective amount of aromatic compound that significantly reduces TSST-1 production has been found to be at least about 0.1 micromolar aromatic compound per gram of absorbent product or non-absorbent substrate. Desirably, the aromatic compound is from about 0.5 micromole per gram of absorbent or non-absorbent substrate to about 100 micromole per gram of absorbent or non-absorbent substrate, and more desirably absorbent or non-absorbable. Ranging from about 1.0 micromole per gram of absorbent substrate to about 50 micromole per gram of absorbent or non-absorbent substrate. “Aromatic compounds” are used in the singular, but those skilled in the art will appreciate that this includes the plural and that various aromatic compounds within the scope of the present invention can be used in combination. I will.
The aromatic compounds of the present invention can be prepared and applied in any suitable form, including but not limited to forms including aqueous solutions, lotions, balms, gels, external preparations, ointments, boluses, suppositories, and the like. It is preferable to be prepared. One skilled in the art will appreciate that other shapes will work equally well.

The aromatic compound can be applied to the absorbent article or non-absorbent substrate using conventional methods for applying the inhibitor to the desired absorbent article or non-absorbent substrate. For example, an integrated tampon without a separate wrap can be immersed directly in a liquid bath with an inhibitory compound and then air dried to remove volatile solvents if necessary. . In compressed tampon, it is best to impregnate any of the elements before compression. Aromatic compounds when incorporated on and / or in the tampon material can be unfastened, weakly attached, bonded, or a combination thereof. As used herein, the term “non-rigid” means that the composition can migrate through the tampon material. In addition, the non-absorbent article can be immersed directly in a liquid bath with the inhibitor compound and then air dried to remove volatile solvents, if desired. Alternatively, the non-absorbent article of the present invention can be sprayed or otherwise coated with the suppressed aromatic compound of the present invention.
The entire tampon absorbent body need not be impregnated with the inhibitor. Optimal results in both economic and functional aspects can be obtained by concentrating the material on or near the outer surface that is most effective in use.

In another embodiment, the aromatic-containing composition may be applied directly over the individual material layers before being incorporated into an article such as the absorbent product being produced. For example, an aqueous solution containing an aromatic compound can be sprayed onto the surface of a porous cover sheet or absorbent layer designed to be incorporated into an absorbent product. This can be done during the production of the individual layers or during the production process of incorporating the layers into the article to be produced.
Nonwoven webs coated with the aromatic-containing composition of the present invention can be made by conventional processes. For example, the aromatic composition can be applied to one or both sides of the moving web. One skilled in the art will appreciate that the application can be done as an inline process or as a separate off-line stage. A web such as spunbond or meltblown nonwoven can be directed through a support roll to a processing station that includes a rotating spray head for application to one side of the web. An optional processing station may include a rotating spray head that applies the aromatic composition to the opposite side of the web. Each processing station typically receives a supply of processing liquid from a reservoir. The treated web can be dried by passing it through a dryer can or other drying means, if necessary, and then wound as a roll or converted into the intended use. Alternative means such as ovens, vent dryers, infrared dryers, air blowers and the like can also be used.
The substantially inhibiting aromatic compound can additionally use one or more conventional pharmaceutically acceptable and compatible carrier materials useful for the desired application. The carrier can be soluble or suspendable with the material used in the absorbent article or on the non-absorbent substrate. Suitable carrier materials for use in the present invention are those well known for use in the cosmetic and medical fields as a base for external preparations, lotions, creams, ointments, aerosols, suppositories, gels and the like. Including.

The aromatic compounds of the present invention can additionally use additives commonly found in pharmaceutical compositions in an industry established manner and in an industry established amount. For example, the composition may be additive and compatible with complementary antimicrobials, antioxidants, anthelmintics, antipruritics, astringents, local anesthetics, or anti-inflammatory agents for complex treatment. Pharmaceutically effective materials can be included.
In another embodiment of the invention, the inhibitory aromatic compounds described above are used in combination with one or more surfactants to reduce TSST-1 production without significantly eliminating beneficial flora. Can do. Surfactants, for example, include C ₈ -C ₁₈ fatty aliphatic alcohol, polyalkoxylated sulfate salt or polyalkoxy ethers linked to polyalkoxylated sulfosuccinate salt, ester, amide, a compound having a glycoside, or an amine bond Can do.

In one embodiment, the suppressed aromatic compounds described herein can be used in combination with an ether compound having the general formula:
R ¹⁰ -O-R ¹¹
Where R ¹⁰ is a linear or branched alkyl or alkenyl group having a chain of about 8 to about 18 carbon atoms, and R ¹¹ is an alcohol, polyalkoxylated sulfate, or polyalkoxyl Selected from sulfonated sulfosuccinates.
The alkyl or R ¹⁰ moieties of ether compounds useful for use in combination with the suppressed aromatic compounds described herein can be derived from saturated and unsaturated fatty acid compounds. Preferred compounds include C ₈ -C ₁₈ fatty acids, preferably fatty acids, but is not limited to, carbon chain length of each 8,10,12,14,16 and 18, caprylic acid, capric acid , Lauric acid, myristic acid, palmitic acid and stearic acid. Highly preferred materials include capric acid, lauric acid, myristic acid.

Preferred unsaturated fatty acids are those having one or two cis double bonds and mixtures of these materials. Suitable materials include myristoleic acid, palmitoleic acid, linolenic acid and mixtures thereof.
Desirably, the R ¹¹ moiety is an aliphatic alcohol that can be ethoxylated or propoxylated for use in an ether composition in combination with the suppressed aromatic compounds described herein. Suitable fatty alcohols include glycerol, sucrose, glucose, sorbitol and sorbitan. Preferred ethoxylated or propoxylated alcohols include glycols such as ethylene glycol, propylene glycol, polyethylene glycol and polypropylene glycol.

Aliphatic alcohols can be ethoxylated or propoxylated by conventional ethoxylated or propoxylated compounds and techniques. The compound is preferably selected from the group consisting of ethylene oxide, propylene oxide, and mixtures thereof, and similar cyclic compounds that provide effective materials.
The R ¹¹ moiety can further comprise polyalkoxylated sulfate and polyalkoxylated sulfosuccinate. These salts can have one or more cations. Preferably, the cation is sodium, potassium or both.
Preferred ether compounds for use in combination with the suppressed aromatic compounds described herein include laureth-3, laureth-4, laureth-5, PPG-5 lauryl ether, 1-0-dodecyl-rac-glycerol, Sodium laureth sulfate, potassium laureth sulfate, laureth (3) disodium sulfosuccinate, laureth (3) dipotassium sulfosuccinate, and polyethylene oxide (2) sorbitol ether.

  According to the present invention, the absorbent article or non-absorbent substrate contains an effective amount of a combination of an inhibitory aromatic compound and an ether compound. The amount of ether compound contained in the absorbent article is at least about 0.1 micromole of ether compound per gram of absorbent article, desirably at least about 0.005 mmol of ether compound per gram of absorbent article. In a preferred embodiment, the absorbent article contains from about 5.0 micromoles of ether compound per gram of absorbent article to about 2 mmoles of ether compound per gram of absorbent article. The amount of ether compound introduced onto the non-absorbent article is at least about 0.0001 millimoles of ether compound per gram of non-absorbent article, desirably at least about 0.001 ether compound per gram of non-absorbent article. 005 mmol. In a preferred embodiment, the non-absorbent article contains from about 0.005 mmol ether compound per gram non-absorbent article to about 2 mmol ether compound per gram non-absorbent article.

Absorbent articles of the present invention containing a combination of two active ingredients include, for example, menstrual tampons, sanitary napkins, panty liners, incontinence underwear, diapers, wound dressings, dental thrombus, medical stops Various absorbent articles including thrombus, surgical thrombus, nasal thrombus and the like can be obtained.
Non-absorbent articles of the present invention containing a combination of two active ingredients include various non-absorbent articles including, for example, incontinence devices, contraceptive barrier devices, contraceptive sponges, irrigators, tampon applicators, etc. It can be.

In accordance with the present invention, the composition comprises an effective amount combination of a suppressed aromatic compound and an ether compound. The amount of ether compound included in the composition is (based on the total weight of the composition) at least about 0.01% (weight / volume), desirably at least about 0.04% (weight / volume). Typically, the composition contains no more than about 0.3% (weight / volume) ether compound. Particularly suitable compositions for use in vaginal cleansing applications include at least about 0.25 mmol / liter, desirably about 10 mmol / liter, most desirably about 0.5 mmol to about 5 mmol / liter of ether compound. contains.
The absorbent article and non-absorbent substrate of the present invention containing the first suppressed aromatic compound and the second suppressed ether compound are those in which the absorbent article or non-absorbent substrate is S.P. It contains both inhibitory compounds in an amount sufficient to substantially inhibit the production of TSST-1 when exposed to Aureus bacteria. Preferably, the combination of inhibitor compounds is such that the absorbent article or non-absorbent substrate is S.P. TSST-1 production when exposed to Aureus is at least about 40%, more preferably at least about 50%, even more preferably at least about 60%, even more preferably at least about 70%, even more preferably Decrease by at least about 80%, even more preferably at least about 90%, even more preferably at least about 95%.

Absorbent articles and non-absorbent substrates of the present invention containing a combination of aromatic and ether-inhibiting compounds can be added to the additives commonly found in pharmaceutical compositions in an industry-established manner and industry. Can be used additionally in the amount established. For example, the composition may be additive and compatible with complementary antimicrobials, antioxidants, anthelmintics, antipruritics, astringents, local anesthetics, or anti-inflammatory agents for complex treatment. Pharmaceutically effective materials can be included.
Typically, the absorbent article has a molar ratio of ether compound to suppressed aromatic compound of from about 1: 6 to about 1: 0.05.

In another embodiment, the suppressed aromatic compounds described herein can be used in combination with an alkyl polyglycoside compound. Suitable alkyl polyglycosides for use in combination with a suppressed aromatic compound include alkyl polyglycosides having the general formula:
H— (Z _n ) —O—R ¹⁴
Here, Z is a sugar residue having 5 to 6 carbon atoms, n is an integer from 1 to 6, and R ¹⁴ is a straight chain or moiety having 8 to 18 carbon atoms. A branched alkyl group. Commercial examples of suitable alkyl polyglycosides with different carbon chain lengths include Glucopon 220, 225, 425, 600 and 625, all of which are available from Henkel (Ambler, PA). All these products are mixtures of alkyl mono- and oligoglucopyranosides with different alkyl group chain lengths based on fatty alcohols derived from coconut oil and / or palm kernel oil. Glucopon 220, 225 and 425 are examples of alkyl polyglycosides that are particularly suitable for use in combination with the inhibitory aromatic compounds of the present invention. Another example of a suitable commercially available alkyl polyglycoside is TL2141, a Glucopon 220 analog available from ICI Surfactants (Wilmington, Del.).

  It is understood that the alkyl polyglycoside referred to herein may consist of a single type of alkyl polyglycoside molecule or, as is typical in this case, may comprise a mixture of different alkyl polyglycoside molecules. I want you to understand. Different alkyl polyglycoside molecules may be isomers and / or alkyl polyglycoside molecules having different alkyl groups and / or sugar moieties. The term isomer of an alkyl polyglycoside refers to an alkyl polyglycoside that contains the same alkyl ether residue but can change the position of the alkyl ether residue in the alkyl polyglycoside, as well as around one or more chiral centers in the molecule. And isomers with different functional group orientations. For example, an alkyl polyglycoside can include a mixture of molecules having a sugar moiety that is a mono-, di-, or oligosaccharide derived from one or more sugar residues having 6 carbon atoms. -, Di-, or oligosaccharides are etherified by reacting with a mixture of fatty alcohols of various carbon chain lengths. Desirably, the alkyl polyglycosides of the present invention contain alkyl groups having an average number of carbon atoms in the alkyl chain of from about 8 to about 12. An example of a suitable alkyl polyglycoside is a mixture of alkyl polyglycoside molecules having an alkyl chain having from about 8 to about 14 or from about 8 to about 12 carbon atoms. One example of a suitable alkyl polyglycoside is a mixture of an alkyl polyglycoside molecule and an alkyl chain having from about 8 to about 10 carbon atoms.

Alkyl polyglycosides used in absorbent articles in combination with suppressed aromatic compounds can be characterized in terms of their hydrophilic lipophilic balance (HLB). This can be calculated based on their chemical structure using techniques well known to those skilled in the art. The HLB of the alkylpolyglycoside used in the present invention is usually within the range of about 10 to about 15. The alkyl polyglycosides of the present invention desirably have an HLB of at least about 12, more preferably from about 12 to about 14.
According to the present invention, the absorbent article or non-absorbent substrate contains a combination of an effective amount of a suppressed aromatic compound and an alkyl polyglycoside compound. The amount of alkyl polyglycoside compound contained in the absorbent article or non-absorbent substrate is at least about 0.0001 mmol of alkyl polyglycoside per gram of absorbent article or non-absorbent substrate, preferably the absorbent article or non-absorbent. There is at least about 0.005 mmol of alkylpolyglycoside per gram of substrate. In a preferred embodiment, the absorbent article or non-absorbent substrate contains from about 0.005 millimoles per gram of absorbent article to about 2 millimoles per gram of absorbent article or non-absorbent substrate.

Absorbent articles of the present invention containing a combination of inhibitors or active ingredients such as aromatic inhibitor compounds and alkyl polyglycoside inhibitor compounds include, for example, menstrual tampons, sanitary napkins, pantilinas, incontinence underwear, Various absorbent articles including diapers, wound dressings, dental thrombus, medical thrombus, surgical thrombus, nasal thrombus and the like can be obtained.
Non-absorbable articles of the present invention containing combinations of inhibitors or active ingredients such as aromatic inhibitor compounds and alkyl polyglycoside inhibitor compounds include, for example, incontinence devices, contraceptive barrier devices, contraceptive sponges, irrigators Various non-absorbent articles including tampon applicators and the like can be obtained.

  In accordance with the present invention, the composition contains an effective amount of a combination of an inhibitory aromatic compound and an alkyl polyglycoside compound. The amount of alkyl polyglycoside compound included in the composition is (based on the total weight of the composition) at least about 0.01% (weight / volume), desirably at least about 0.04% (weight / volume). . Typically, the composition contains no more than about 0.3% (weight / volume) ether compound. Particularly suitable compositions for use in vaginal cleansing applications include at least about 0.25 mmol / liter, desirably about 10 mmol / liter, most desirably about 0.5 mmol to about 5 mmol / liter of ether compound. contains.

  The absorbent article and non-absorbent substrate of the present invention containing the first inhibitory aromatic compound and the second inhibitory ether compound are those in which the absorbent article or non-absorbent substrate is S.P. It contains both inhibitory compounds in an amount sufficient to substantially inhibit TSST-1 production when exposed to Aureus bacteria. Preferably, the combination of inhibitor compounds is such that the absorbent article or non-absorbent substrate is S.P. TSST-1 production when exposed to Aureus is at least about 40%, more preferably at least about 50%, even more preferably at least about 60%, even more preferably at least about 70%, even more preferably Decrease by at least about 80%, even more preferably at least about 90%, and even more preferably at least about 95%.

ここで、カルボニル炭素を含むＲ¹⁷は、８個から１８個の炭素原子を有するアルキル基であり、Ｒ¹⁸及びＲ¹⁹は、水素か、又はエステル基、エーテル基、アミン基、ヒドロキシル基、カルボキシル基、カルボン酸塩、スルホン酸基、スルホン酸塩、及びこれらの混合物から選択される官能基と置換されても置換されなくても良い１個から１２個までの炭素原子を有するアルキル基から別々に選択される。 Absorbent articles or non-absorbent substrates of the present invention containing a combination of aromatic and alkyl polyglycoside inhibitor compounds are commonly used in pharmaceutical compositions and in an industry established manner. Can be used additionally in the amount established in For example, the composition may be additive and compatible with complementary antimicrobials, antioxidants, anthelmintics, antipruritics, astringents, local anesthetics, or anti-inflammatory agents for complex treatment. Pharmaceutically effective materials can be included.
Typically, the absorbent article has a molar ratio of suppressed aromatic compound to alkyl glycoside compound of from about 1: 1 to about 1: 0.005. Typically, the non-absorbent substrate has a molar ratio of suppressed aromatic compound to alkyl glycoside compound of from about 1: 1 to about 1: 0.05.
In another embodiment, the suppressed aromatic compounds described herein can be used in combination with an amide-containing compound having the general formula:

Here, R ¹⁷ containing a carbonyl carbon is an alkyl group having 8 to 18 carbon atoms, and R ¹⁸ and R ¹⁹ are hydrogen or an ester group, an ether group, an amine group, a hydroxyl group, a carboxyl group. Separate from alkyl groups having from 1 to 12 carbon atoms that may or may not be substituted with functional groups selected from groups, carboxylates, sulfonic acid groups, sulfonates, and mixtures thereof Selected.

R ¹⁷ can be derived from saturated and unsaturated fatty acid compounds. Suitable compounds include C ₈ -C ₁₈ fatty acids, preferably fatty acids include, but are not limited to, caprylic acid, capric acid, lauric acid, myristic acid, palmitic acid and stearic acid, and these carbon chains The lengths are 8, 10, 12, 14, 16 and 18 respectively. Highly preferred materials include capric acid, lauric acid and myristic acid.
Preferred unsaturated fatty acids are those having one or two cis double bonds and mixtures of these materials. Suitable materials include myristoleic acid, palmitoleic acid, linolenic acid and mixtures thereof.
The R ¹⁸ and R ¹⁹ moieties can be the same or different and are each selected from hydrogen and an alkyl group having a carbon chain having from 1 to 12 carbon atoms. R ¹⁸ and R ¹⁹ alkyl groups can be linear or branched and can be saturated or unsaturated. When R ¹⁸ and / or R ¹⁹ is an alkyl moiety having a carbon chain of at least two carbons, the alkyl group can be from ester, ether, amine, hydroxyl, carboxyl, carboxylate, sulfonic acid, sulfonate. One or more selected substituents can be included. The salt can have one or more cations selected from sodium, potassium, or both. The salt can have one or more cations selected from sodium, potassium, or both.

Preferred amide compounds for use in combination with the suppressed aromatic compounds described herein include sodium lauryl sarcosinate, lauryl amide monoethanolamide, lauryl amide diethanolamide, lauryl amide propyldimethylamine, lauryl amide monoethanolamide sulfosuccinate. Disodium acid and disodium lauroamphodiacetate are included.
According to the present invention, the absorbent article or non-absorbent substrate contains a combination of an effective amount of a suppressed aromatic compound and an amide-containing compound. The amount of amide-containing compound contained in the absorbent article or non-absorbent substrate is at least about 0.0001 mmol of nitrogen-containing compound per gram of absorbent article or non-absorbent substrate, preferably the absorbent article or non-absorbent The nitrogen-containing compound is at least about 0.005 millimoles per gram of conductive substrate. In preferred embodiments, the absorbent article or non-absorbent substrate is at least about 0.005 millimoles per gram of absorbent article or non-absorbent substrate to at least about 2 millimoles per gram of absorbent article or non-absorbent substrate. Containing.
According to the present invention, the composition contains a combination of an effective amount of a suppressed aromatic compound and an amide-containing compound. The amount of amide compound included in the composition is (based on the total weight of the composition) at least about 0.01% (weight / volume), desirably at least about 0.04% (weight / volume). Typically, the composition contains greater than about 0.3% (weight / volume) amide compound. Particularly suitable formulations for use in vaginal cleansing applications are at least about 0.25 mmol / liter, desirably more than about 5 mmol / liter, most desirably about 0.5 to about 3 mmol / liter of amide compound. Containing.

Absorbent articles of the present invention containing a combination of inhibitors or active ingredients such as aromatic inhibitor compounds and amide-containing inhibitor compounds include, for example, menstrual tampons, sanitary napkins, panty liners, incontinence underwear, diapers Various absorbent articles including wound dressings, dental thrombus, medical thrombus, surgical thrombus, nasal thrombus and the like can be obtained.
Non-absorbable articles of the present invention containing combinations of inhibitors or active ingredients such as aromatic and amide-containing inhibitor compounds include, for example, incontinence devices, contraceptive barrier devices, contraceptive sponges, irrigators, tampon applicators It can be set as various nonabsorbent articles including these.
The absorbent article or non-absorbent substrate of the present invention comprising the first inhibitory aromatic compound and the second inhibitory amide-containing compound is an absorbent article or non-absorbent substrate. It contains both inhibitory compounds in an amount sufficient to substantially inhibit the production of TSST-1 when exposed to Aureus bacteria. In combination with the inhibitor compound, the absorbent article or non-absorbent substrate is S.P. TSST-1 production when exposed to aureus is preferably at least about 40%, more preferably about 50%, more preferably about 60%, more preferably about 70%, more preferably about 80%, More preferably, it is reduced by about 90%, more preferably about 95%.

ここで、Ｒ²⁰は、約８個から約１８個までの炭素原子を有するアルキル基であり、Ｒ²¹及びＲ²²は、水素と、１個から１８個までの炭素原子を有し、ヒドロキシル、カルボキシル、カルボン酸塩、及びイミダゾリンからなる群から選択される１つ又はそれ以上の置換部分を有することができるアルキル基とからなる群から別々に選択される。芳香族化合物とアミン化合物の組み合わせは、グラム陽性菌からのエキソプロテインの産生を実質的に抑制するのに効果的である。 Absorbent articles or non-absorbent substrates of the present invention that contain a combination of aromatic and amide-containing inhibitor compounds are commonly used in pharmaceutical compositions, in the industry and in the industry. Can be used additionally in the amount established. For example, the composition may be additive and compatible with complementary antimicrobials, antioxidants, anthelmintics, antipruritics, astringents, local anesthetics, or anti-inflammatory agents for complex treatment. Pharmaceutically effective materials can be included.
Typically, the absorbent article or non-absorbent substrate has a molar ratio of suppressed aromatic compound to amide-containing compound of from about 1: 2 to about 1: 0.05.
In another embodiment, the inhibitory compounds described herein can be used in combination with an amine compound having the general formula:

Wherein R ²⁰ is an alkyl group having from about 8 to about 18 carbon atoms, R ²¹ and R ²² are hydrogen, having from 1 to 18 carbon atoms, hydroxyl, Separately selected from the group consisting of an alkyl group that can have one or more substituents selected from the group consisting of carboxyl, carboxylate, and imidazoline. A combination of an aromatic compound and an amine compound is effective in substantially suppressing exoprotein production from Gram-positive bacteria.

Desirably, R ²⁰ includes, but is not limited to, caprylic acid, capric acid, lauric acid, myristic acid, palmitic acid and stearic acid, whose carbon chain length is 8, 10, 12, 14, 16, and Derived from a fatty acid compound that is 18. Highly preferred materials include capric acid, lauric acid and myristic acid. Preferred unsaturated fatty acids are those having one or two cis double bonds and mixtures of these materials. Suitable materials include myristoleic acid, palmitoleic acid, linolenic acid and mixtures thereof.
In accordance with the present invention, the composition comprises an effective amount combination of a suppressed aromatic compound and an ether compound. The amount of amine compound included in the composition is (based on the total weight of the composition) at least about 0.01% (weight / volume), desirably at least about 0.04% (weight / volume). Typically, the composition contains no more than about 0.3% (weight / volume) ether compound. Particularly suitable compositions for use in vaginal irrigation applications are at least about 0.25 mmol / liter, desirably no more than about 5 mmol / liter, most desirably about 0.5 mmol to about 3 mmol / liter ether. Contains amine compounds up to compounds.

ここで、Ｒ²³は、アミンと会合するアニオン部分であり、約８個から約１８個までの炭素原子を有するアルキル基から誘導され、Ｒ²⁴、Ｒ²⁵及びＲ²⁶は、水素と、１個から１８個までの炭素原子を有し、ヒドロキシル、カルボキシル、カルボン酸塩、イミダゾリンからなる基から選択される１つ又はそれ以上の置換部分を有することができるアルキル基とからなる群から別々に選択される。Ｒ²⁴、Ｒ²⁵及びＲ²⁶は、飽和又は不飽和とすることができる。望ましくは、Ｒ²³は、ポリアルコキシル化アルキル硫酸塩である。アミン塩の例証となる好ましい化合物は、ＴＥＡラウレス硫酸塩である。
本発明によると、吸収性物品又は非吸収性基体は、有効量の抑制芳香族化合物とアミン及び／又はアミン塩化合物が組み合わされたものを含有する。吸収性物品又は非吸収性基体に含まれるアミン及び／又はアミン塩化合物の量は、吸収性物品又は非吸収性基体１グラム当たりエーテルが少なくとも約０．０００１ミリモルであり、好ましくは吸収性物品又は非吸収性基体１グラム当たりエーテルが少なくとも約０．００５ミリモルである。好ましい実施形態においては、吸収性物品又は非吸収性基体は、吸収性物品又は非吸収性基体１グラム当たり少なくとも約０．００５ミリモルから吸収性物品又は非吸収性基体１グラム当たり少なくとも約２ミリモルまでを含有する。 In another embodiment, the amine compound can be an amine salt having the general formula:

Where R ²³ is an anion moiety associated with an amine and is derived from an alkyl group having from about 8 to about 18 carbon atoms, R ²⁴ , R ²⁵ and R ²⁶ are hydrogen, Independently selected from the group consisting of alkyl groups having from 1 to 18 carbon atoms and having one or more substituents selected from the group consisting of hydroxyl, carboxyl, carboxylate, imidazoline Is done. R ²⁴ , R ²⁵ and R ²⁶ can be saturated or unsaturated. Desirably, R ²³ is a polyalkoxylated alkyl sulfate. A preferred compound illustrative of an amine salt is TEA laureth sulfate.
According to the present invention, the absorbent article or non-absorbent substrate contains a combination of an effective amount of a suppressed aromatic compound and an amine and / or amine salt compound. The amount of amine and / or amine salt compound contained in the absorbent article or non-absorbent substrate is at least about 0.0001 mmol ether per gram of absorbent article or non-absorbent substrate, preferably the absorbent article or The ether is at least about 0.005 mmol per gram of non-absorbent substrate. In preferred embodiments, the absorbent article or non-absorbent substrate is at least about 0.005 millimoles per gram of absorbent article or non-absorbent substrate to at least about 2 millimoles per gram of absorbent article or non-absorbent substrate. Containing.

Absorbent articles of the present invention containing a combination of two active ingredients include, for example, menstrual tampons, sanitary napkins, panty liners, incontinence underwear, diapers, trauma dressings, dental thrombus, medical stops Various absorbent articles including thrombus, surgical thrombus, nasal thrombus and the like can be obtained.
Non-absorbable articles of the present invention containing a combination of an inhibitory or active ingredient such as an aromatic inhibitory compound and an amide-containing inhibitory compound include, for example, incontinence devices, contraceptive barrier devices, contraceptive sponges, irrigators, It can be set as various non-absorbent articles including a tampon applicator and the like.
The absorbent article or non-absorbent substrate of the present invention containing the first inhibitory aromatic compound and the second inhibitory amine and / or amine salt compound is an absorbent article or non-absorbent substrate. It contains both inhibitory compounds in an amount sufficient to substantially inhibit the production of TSST-1 when exposed to Aureus bacteria. In combination with the inhibitor compound, the absorbent article or non-absorbent substrate is S.P. TSST-1 production when exposed to aureus is preferably at least about 40%, more preferably about 50%, more preferably about 60%, more preferably about 70%, more preferably about 80%, More preferably, it is reduced by about 90%, more preferably about 95%.

According to the present invention, the composition contains an effective amount of a combination of an effective amount of an inhibitory aromatic salt and an amine salt. The amount of amine salt included in the composition is (based on the total weight of the composition) at least about 0.01% (weight / volume), desirably at least about 0.04% (weight / volume). . Typically, the composition contains no more than about 0.3% (w / v) amine salt compound. Particularly suitable compositions for use in vaginal cleansing applications are at least about 0.25 mmol / liter, desirably no more than about 5 mmol / liter, most desirably about 0.5 to about 3 mmol / liter amine salt. Contains compounds.
The absorbent article or non-absorbent substrate of the present invention containing a combination of an aromatic inhibitor compound and an amine and / or amine salt inhibitor compound has been established in the industry as an additive commonly found in pharmaceutical compositions. It can be used additionally in a manner and in an amount established in the industry. For example, the composition may be additive and compatible with complementary antimicrobials, antioxidants, anthelmintics, antipruritics, astringents, local anesthetics, or anti-inflammatory agents for complex treatment. Pharmaceutically effective materials can be included.
Typically, the absorbent article or non-absorbent substrate has a molar ratio of suppressed aromatic compound to amine and / or amine salt compound of from about 1: 2 to about 1: 0.05. Typically, the non-absorbent article or substrate has a molar ratio of suppressed aromatic compound to amine and / or amine salt compound of from about 1: 2 to about 1: 0.01.
The present invention is illustrative of the invention and is for illustrative purposes only and is not to be construed as limiting the scope of the invention or the manner in which the invention may be practiced. Illustrated by example.

(Example 1)
In this embodiment, S.M. The effect of various test compounds on aureus growth and TSST-1 production was measured. The desired concentration of test compound (expressed as a percentage of active compound) was placed in 10 mL of growth medium in a sterile 50 mL polypropylene conical tube (Sarstedt, Newton, NC).
Growth medium was prepared by dissolving 37 grams of Brain Heart Infusion Medium (BHI) (Difco Laboratories, Cockeysville, MD) in 880 mL of distilled water and sterilizing the medium according to the manufacturer's instructions. Prepared. BHI was supplemented with fetal calf serum (FBS) (100 mL) (Sigma Chemical, St. Louis, MO). Magnesium chloride hexahydrate (0.021 M, 10 mL) (Sigma Chemical Co., St. Louis, MO) was added to the BHI-FBS mixture. Finally, L-glutamine (0.027 M, 10 mL) (Sigma Chemical Co., St. Louis, MO) was added to the mixture.

Compounds to be tested include phenylethyl alcohol, benzyl alcohol, and 2-hydroxybenzamide. The test compound was both liquid and solid. Liquid test compounds were added directly to growth medium and diluted with growth medium to the desired final concentration. The solid test condensate was dissolved in spectrophotometric grade (Sigma Chemical) methanol at a concentration that allowed 200 microliters of solution to be added to 10 mL of growth medium for the highest concentration tested. Each test compound dissolved in methanol was added to the growth medium in the amount required to achieve the desired final concentration.
In preparation for inoculating a test tube containing a growth medium containing a test compound, an inoculum culture was prepared as follows. S. Aureus (MN8) was inoculated linearly on tryptic soy agar plates (TSA, Difco Laboratories, Cockeysville, MD) and cultured at 35 degrees Celsius. Test microorganisms were obtained from Dr. Pat Schrivevert, Department of Microbiology, Minnesota Medical University, Minneapolis, Minnesota. After 24 hours of constant temperature incubation, 3 to 5 individual colonies were picked using a sterile inoculation loop and used to inoculate 10 mL of growth medium. Inoculated growth medium tubes were cultured at 35 degrees Celsius in atmospheric air. After incubation for 24 hours, the culture was removed from the incubator and mixed well with an S / P brand vortex mixer. A second test tube containing 10 mL of growth medium was inoculated with 0.5 mL of the above 24-hour culture and cultured at 35 degrees Celsius in atmospheric pressure air. After incubation for 24 hours, the culture was removed from the incubator and mixed well with an S / P brand vortex mixer. The optical density of the culture was measured with a microplate reader (Model EL309 Bio-Tek Instruments, Winuski, VT). The amount of inoculum required to give 5 × 10 ⁶ CFU / mL in 10 mL growth medium was determined using a standard curve.

This example includes growth medium test tubes containing various concentrations of test compound, growth medium test tubes containing no test compound (control), and growth containing 20 to 400 microliters of methanol. Medium test tubes (control) were included. Each test tube was inoculated with the amount of inoculum determined as described above. These test tubes were covered with foam plugs (Jadece Industries, Inc., Plastic foam plugs from Jace Industries, acquired from VWR Scientific Products, South Plainfield, NJ). Tubes were incubated at 35 ° C in air at atmospheric pressure with 5% by volume of CO _2. After 24 hours of constant temperature culture, these test tubes were removed from the incubator, the optical density (600 nm) of the culture was measured, and the culture was Aureus colony forming units were assayed and prepared for analysis of TSST-1 as described below.
The number of colony forming units per mL after incubation at constant temperature was measured by a standard plate count procedure. In preparation for analysis of TSST-1, the culture medium was centrifuged and the supernatant was then filter sterilized through an Automatic 5 syringeless filter (Whatman, Clifton, NJ) with a pore size of 0.2 micrometers. The resulting liquid was frozen at −70 ° C. until assayed.

The amount of TSST-1 per mL was determined by a non-antagonistic sandwich enzyme-linked immunosorbent assay (ELISA). Culture medium and TSST-1 reference standard were assayed in triplicate. The method used was as follows. Rabbit anti-TSST-1 polyclonal IgF conjugated with four reagents: TSST-1 (# TT-606), rabbit anti-TSST-1 polyclonal IgG (LTI-101), and horseradish peroxidase (LTC-101). And normal rabbit serum (NRS) certified as anti-TSST-1 free (NRS-10) was purchased from Toxin Technology (Sarasota, Florida). A 10 microgram / millimeter solution of rabbit anti-TSST-1 polyclonal IgG was prepared in phosphate buffered saline (PBS) (pH = 7.4). PBS consists of 0.016 mole NaH ₂ PO ₄ , 0.004 mole NaH ₂ PO ₄ —H ₂ O, 0.003 mole KCl, and 0.137 mole NaCl (Sigma, St. Louis, MO). (Chemical). 100 microliters of rabbit anti-TSST-1 polyclonal IgG solution was pipetted into wells in a polystyrene microplate (Nunc-Denmark, catalog number 439454). The plate was capped and incubated overnight at room temperature. Unbound antitoxin was removed by draining to dryness. TSST-1 is a phosphate buffer containing 0.05% (vol / vol) Tween-20 (PBS-Tween) (Sigma Chemical Co., St. Louis, MO) and 1% (vol / vol) NRS. Dilute to 10 nanograms / milliliter in PBS with saline (pH = 7.4) and incubate overnight at 4 ° C. The test sample was mixed with 1% (vol / vol) NRS and incubated at 4 ° C. overnight. The plates were treated with 100 microliters of a 1% solution of casein sodium salt in PBS (Sigma Chemical Co., St. Louis, MO), the plates were capped and incubated at 35 ° C. for 1 hour. Unbound BSA was removed by washing 3 times with PBS-Tween. A reference standard of TSST-1 treated with NRS (10 nanograms / milliliter), a test sample treated with NRS, and a reagent control were placed in 200 microliters in each well on the first and seventh columns of the plate. Pipette in liter volumes. To the remaining wells, 100 microliters of PBS-Tween was added. The TSST-1 reference standard and test sample were then serially diluted 6-fold in PBS-Tween by transferring 100 microliters from well to well. These samples were mixed before transfer by repeated aspiration and pressure. Test samples and TSST-1 reference standard were assayed three times. Thereafter, the cells were cultured at 35 ° C. for 1.5 hours, washed 5 times with PBS-T and 3 times with distilled water in order to remove unbound toxin. Rabbit anti-TSST-1 polyclonal IgG conjugated with horseradish peroxidase was diluted according to the manufacturer's instructions and 50 microliters was added to each microtiter well except well A-1, which was a conjugated control well. . The plates were covered and incubated at 35 degrees Celsius for 1 hour.

  Following incubation, the plates were washed 5 times with PBS-Tween and 3 times with distilled water. Following such washing, the wells were treated with 100 microliters of horseradish peroxidase substrate buffer containing 5 milligrams of o-phenylenediamine and 5 microliters of 30% hydrogen peroxide in 11 mL of citrate buffer (pH 5.5). did. The citrate buffer was prepared from 0.012 M anhydrous citric acid and 0.026 mol dibasic sodium phosphate. The plate was incubated at 35 degrees Celsius for 15 minutes. The reaction was stopped by adding 50 microliters of 5% sulfuric acid solution. The intensity of the color reaction in each well was evaluated using a BioTek Model EL309 microplate reader (OD490 nanometer). The TSST-1 concentration in the test sample was determined from the reference toxin regression equation derived through each assay procedure. The effectiveness of the compounds in inhibiting TSST-1 production is shown in Table 1 below.

Ｎ／Ａ＝適用されない According to the present invention, the data in Table 1 shows that the S.P. It shows that aureus (MN8) produces very little TSST-1 in the presence of aromatic compounds. Aromatic compounds reduced exotoxin production from about 91% to about 96%. However, although the amount of toxin produced was greatly reduced, The effect on the proliferation of aureus cells was very slight, if any.
(Table 1)

N / A = not applicable

Ｎ／Ａ＝適用されない (Example 2)
In this embodiment, S.M. The effect of various test compounds on aureus growth and TSST-1 production was determined. The effect of the test compound tested in Example 2 was determined by setting the desired concentration expressed as a percentage of active compound in 10 mL of growth medium as shown in Example 1. The test compound was then tested and evaluated as in Example 1.
According to the present invention, Table 2 shows S. cerevisiae as compared to the control. It shows that aureus (MN8) produces very little TSST-1 in the presence of aromatic compounds. Aromatic compounds reduced exotoxin production from about 82% to about 97%. However, although the amount of toxin produced was greatly reduced, The effect on the growth of aureus cells was very slight, if any.
(Table 2)

N / A = not applicable

Ｎ／Ａ＝適用されない (Example 3)
In this embodiment, S.M. The effect of various test compounds on aureus growth and TSST-1 production was determined. The effect of the test compound tested in Example 3 was determined by setting the desired concentration expressed as a percentage of active compound in 10 mL of growth medium as shown in Example 1. The test compound was then tested and evaluated as in Example 1.
According to the present invention, Table 3 shows that S. It shows that aureus (MN8) produces very little TSST-1 in the presence of aromatic compounds. Aromatic compounds reduced exotoxin production from about 69% to about 98%. However, although the amount of toxin produced was greatly reduced, The effect on the growth of aureus cells was very slight, if any.













(Table 3)

N / A = not applicable

Ｎ／Ａ＝適用されない Example 4
In this embodiment, S.M. The effect of various test compounds on aureus growth and TSST-1 production was determined. The effect of the test compound tested in Example 4 was determined by setting the desired concentration expressed as a percentage of active compound in 10 mL of growth medium as shown in Example 1. The test compound was then tested and evaluated as in Example 1.
According to the present invention, Table 4 shows S. cerevisiae as compared to the control. It shows that aureus (MN8) produces very little TSST-1 in the presence of aromatic compounds. Aromatic compounds reduced exotoxin production from about 79% to about 98%. However, although the amount of toxin produced was greatly reduced, The effect on the proliferation of aureus cells was very slight, if any.
(Table 4)

N / A = not applicable

Ｎ／Ａ＝適用されない (Example 5)
In this example, S. cerevisiae in the presence of phenylethyl alcohol is used. aureus growth and TSST-1 production are described in S. aureus. It was determined using TSST-1 producing strains of different aureus. S. aureus FRI-1187 and FRI-1169 are available from Dr. of Food Research Institute (Madison, Wis.). Available as a lyophilized culture from the Merlin Bergdoll stock collection. The effect of phenylethyl alcohol was measured by setting the desired concentration expressed as a percentage of active compound in 10 mL of growth medium as in Example 1. Next, phenylethyl alcohol was tested and evaluated as in Example 1.
According to the present invention, Table 5 shows S. cerevisiae as compared to the control. It shows that aureus (MN8) produces very little TSST-1 in the presence of phenylethyl alcohol. Phenylethyl alcohol reduced exotoxin production from FRI-1169 cultures from about 95% to about 100%. Phenylethyl alcohol also greatly reduces exoprotein production from FRI-1187 cultures. However, although the amount of toxin produced was greatly reduced, The effect on the growth of aureus cells was very slight, if any.
(Table 5)

N / A = not applicable

(Example 6)
In this example, the effect of a test compound in combination with a surfactant was tested using a checkerboard experimental design. As a result, S.I. It became possible to evaluate the interaction of the two test compounds on aureus growth and TSST-1 production. In a test tube, four concentrations of one test compound (including zero) were combined with five concentrations of a second test compound (including zero). In this example, phenylethyl alcohol (0%, 0.5%, 0.3%, 0.15%, and 0.05% was added to Cetol 1414E (Milles-3 myristate) (10 mM, 5 mM, 2.5 mM). And 0) The test solution was prepared by other techniques as described in Example 1 and evaluated in the same way as Example 1.
As shown in Table 6 below, phenylethyl alcohol improves the suppression of TSST-1 production at all concentrations of Cetol 1414E, and vice versa. The impact appears to be additive.


(Table 6)

(Example 7)
In this example, S. using a standard hemolytic assay. The effects of phenylethyl alcohol, 4-hydroxybenzoic acid and methyl ester on the production of alpha toxin from Aureus strain RN6390 were evaluated.
S. Aureus alpha toxin is a hemolytic exoprotein that leads to target cell membrane damage and cell death. This is produced under environmental conditions similar to those seen in TSST-1 production. S. The effect of the test compound on aureus growth and alpha toxin production is carried out by setting the desired concentration expressed as a percentage of active compound in 100 mL growth medium in 500 mL freezer capped with aluminum foil. It was. Growth medium and inoculum were prepared as shown in Example 1. The freezer was incubated in a 37 ° C. water bath with a swirl shaker set at 180 rpm. After growth, periodic optical density measurements were taken at 600 nm. When an optical density growth of 1.0 was obtained, 10 ml aliquots were taken for analysis. Plate counts were performed on the aliquots to determine cell counts and medium purity. The remaining culture was centrifuged at 2500 rpm for 15 minutes and the resulting supernatant filter was sterilized and frozen at −70 ° C. until assayed.

Ｎ／Ａ＝適用されない

（表８）

Ｎ／Ａ＝適用されない Defibrinated rabbit erythrocytes (Hema Resources, Aurora, Oregon) were washed three times with Tris physiological buffer and resuspended to a concentration of 0.5% (volume / volume). Tris physiological buffer consists of 50 mM Trizma® hydrochloride / Trizma base and 100 mM sodium chloride with a final pH of 7.0. The culture supernatant was serially diluted with Tris physiological buffer from 1: 2 to 1: 256. Each of the 100 microliter dilutions was added to 900 microliters of rabbit erythrocytes. Each dilution was prepared in triplicate. Tubes were incubated for 30 minutes at 37 ° C. Samples were centrifuged at 800 xg for 6 minutes. Two 200 microliter aliquots of each tube were transferred to a microtiter plate and the optical density was measured at 410 nm. A control fluid was used in place of the culture supernatant containing Tris physiological buffer (zero lysis), 10% sodium dodecyl sulfate (100% lysis) and sterile growth medium containing the test compound. The activity unit is expressed as the reciprocal of the dilution of each test sample giving 50% dissolution in the sample adjusted to the same initial optical density. As shown in Tables 7 and 8 below, both phenylethyl alcohol and 4-hydroxybenzoic acid methyl ester greatly reduce alpha toxin production.
(Table 7)

N / A = not applicable

(Table 8)

N / A = not applicable

Ｎ／Ａ＝適用されない
以下の表９に示すように、Ｇｌｕｃｏｐｏｎの全ての濃度において、フェニルエチルアルコールは、ＴＳＳＴ−の産生の抑制を向上させ、逆の場合も同様である。効果は加法的なものとなるように見える。 (Example 8)
In this example, the effect of phenylethyl alcohol in combination with Glucopon was evaluated using a checkerboard experimental design. This is because S.A. Allows assessment of the interaction of two test compounds on aureus growth and TSST-1 production.
In 20 test tube arrays, 5 concentrations of phenylethyl alcohol (0.5%, 0.3%, 0.15%, 0.05%, and 0.0%) and 4 concentrations of Glucopon (1. Combined with 4 concentrations of 5 mM, 0.75 mM, 0.25 mM and 0 mM). For example, test tube # 1 contains 0 mM Glucopon and 0.5% phenylethyl alcohol (volume / volume) in 10 mL of growth medium (as prepared in Example 1). Each of test tubes # 1- # 20 contains a unique combination of Glucopon and phenylethyl alcohol. These combinations were tested and evaluated as in Example 1. S. The effects of test compounds on aureus growth and TSST-1 production are shown in Table 9 below.






(Table 9)

N / A = not applicable As shown in Table 9 below, at all concentrations of Glucopon, phenylethyl alcohol improves the suppression of TSST- production, and vice versa. The effect seems to be additive.

Ｎ／Ａ＝適用されない
上記の観点から、本発明の幾つかの目的が達成されることが分るであろう。本発明の範囲から逸脱することなく、上述の吸収性物品において種々の変更をなし得るので、上記の明細書に包含されるすべての内容が例証と解釈され、限定の意味として解釈されないことが意図されている。 (Example 10)
In this example, the effect of Cetiol in combination with paraaminobenzoic acid was evaluated using a checkerboard experimental design. This is because S.A. Allows assessment of the interaction of two test compounds on aureus growth and TSST-1 production.
In 20 test tube arrays, 5 concentrations of paraaminobenzoic acid (0.05%, 0.09%, 0.19%, 0.38%, and 0.0%) and 4 concentrations of Cetiol (2. 5 mM, 5 mM, 10 mM and 0 mM). For example, test tube # 1 contains 0% paraaminobenzoic acid and 0 mM Cetiol (volume / volume) in 10 mL of growth medium (as prepared in Example 1). Each of test tubes # 1- # 20 contains a unique combination of Cetiol and paraaminobenzoic acid. These combinations were tested and evaluated as in Example 1. S. The effects of test compounds on aureus growth and TSST-1 production are shown in Table 10 below.









(Table 10)

N / A = not applicable In view of the above, it will be seen that the several objects of the invention are achieved. Since various changes may be made in the above-described absorbent article without departing from the scope of the present invention, all contents included in the above specification are intended to be illustrative and not intended to be limiting. Has been.

Claims (86)

An absorbent exoprotein-suppressing article comprising an absorbent material and an effective amount of a first active ingredient for use in or near the skin to absorb bodily fluids, the first active ingredient Is the general formula:

Wherein R ¹ is H,

^{-OR 5, -R 6 C (O} ) H, -R 6 OH, -R 6 COOH, -OR 6 OH, -OR 6 COOH, -C (O) NH 2,

And NH ₂ and their salts, R ⁵ is a monovalent saturated or unsaturated aliphatic hydrocarbyl moiety, R ⁶ is a divalent saturated or unsaturated aliphatic hydrocarbyl moiety, R ⁷ is a trivalent saturated or unsaturated aliphatic hydrocarbyl moiety, R ⁸ is a monovalent substituted or unsubstituted saturated or unsaturated aliphatic hydrocarbyl moiety, which may or may not be intervened by heteroatoms, ² , R ³ and R ⁴ are independently selected from the group consisting of H, OH, COOH, and —C (O) R ⁹ , wherein R ⁹ is hydrogen or a monovalent saturated or unsaturated aliphatic hydrocarbyl moiety; Absorbent exoprotein-suppressing article, wherein the first active ingredient is effective to suppress exoprotein production from Gram-positive bacteria.   The first active ingredient is 2-phenylethanol, benzyl alcohol, trans-cinnamic acid, 4-hydroxybenzoic acid, methyl ester, 2-hydroxybenzoic acid, 2-hydroxybenzamide, acetyltyrosine, 3,4,5-tri The hydroxybenzoic acid, lauryl 3,4,5-trihydroxybenzoate, phenoxyethanol, 4-hydroxy-3-methoxybenzoic acid, p-aminobenzoic acid, and acetaminophen. Absorbent exoprotein suppression article.   The absorbent exoprotein-suppressing article of claim 1, wherein the first active ingredient is present in an amount of at least about 0.1 micromole per gram of absorbent article.   The absorptive exoprotein-suppressing article according to claim 1, wherein the first active ingredient is effective to substantially suppress TSST-1 production from Staphylococcus aureus.   The article is selected from the group consisting of menstrual tampons, sanitary napkins, panty liners, incontinence underwear, diapers, wound dressings, dental thrombus, medical thrombus, surgical thrombus, and nasal thrombus The absorbent exoprotein-suppressing article according to claim 1, wherein Ether connecting the C ₈ -C ₁₈ fatty aliphatic alcohol, an ester, amide, further comprising glycosides, or a second active ingredient an effective amount with an amine linkage, the second active ingredient, exo from Gram-positive bacteria 2. The absorbent exoprotein-suppressing article according to claim 1, which is effective for substantially suppressing protein production. General formula, ie
R ¹⁰ —O—R ¹¹
And wherein R ¹⁰ is a linear or branched alkyl having from 8 to about 18 carbon atoms, or a linear or branched alkenyl, and R ¹¹ is , Alcohol, polyalkoxylated sulfate, and polyalkoxylated sulfosuccinate, wherein the second active ingredient is effective to substantially inhibit exoprotein production from Gram-positive bacteria The absorbent exoprotein-suppressing article according to claim 1.   The second active ingredient is laureth-3, laureth-4, laureth-5, PPG-5 lauryl ether, 1-0-dodecyl-rac-glycerol, sodium laureth sulfate, potassium laureth sulfate, laureth (3) disulfosuccinate The absorbent exoprotein-suppressing article according to claim 7, wherein the article is selected from the group consisting of sodium, laureth (3) dipotassium sulfosuccinate, and polyethylene oxide (2) sorbitol ether.   8. The absorbent exoprotein-suppressing article of claim 7, wherein the second active ingredient is present in an amount of at least about 0.1 micromole per gram of absorbent article.   The absorbable exoprotein-suppressing article according to claim 7, wherein the second active ingredient is effective to substantially suppress TSST-1 production from Staphylococcus aureus.   The absorbent article comprises a menstrual tampon, sanitary napkin, panty liner, incontinence underwear, diaper, wound dressing, dental thrombus, medical thrombus, surgical thrombus, and nasal thrombus The absorbent exoprotein-suppressing article according to claim 7, which is selected from the group consisting of:   The absorbable exoprotein of claim 1, further comprising an effective amount of a second active ingredient comprising an alkyl polyglycoside effective to substantially inhibit exoprotein production from Gram-positive bacteria. Suppression article.   The absorbent article comprises a menstrual tampon, sanitary napkin, panty liner, incontinence underwear, diaper, wound dressing, dental thrombus, medical thrombus, surgical thrombus, and nasal thrombus The absorbent exoprotein-suppressing article according to claim 12, characterized in that it is selected from the following.   13. The absorbent exoprotein-suppressing article of claim 12, wherein the second active ingredient is present in an amount of at least about 0.0001 millimoles per gram of absorbent article.   13. The absorbent exoprotein-suppressing article according to claim 12, wherein the alkyl polyglycoside is selected from Glucopon220, Glucopon225, Glucopon425, Glucopon600, Glucopon625, and TL2141.   And further comprising an effective amount of a second active ingredient selected from the group consisting of glycerol monolaurate and milles-3-myristate, said active ingredient substantially inhibiting exoprotein production from Gram-positive bacteria. The absorbent exoprotein-suppressing article according to claim 1, which is effective. General formula, i.e.

Further comprising an effective amount of a second active ingredient, wherein R ¹⁷ containing a carbonyl carbon is an alkyl group having from 8 to 18 carbon atoms, and R ¹⁸ and R ¹⁹ are hydrogen, Or substituted or unsubstituted with a functional group selected from an ester group, an ether group, an amine group, a hydroxyl group, a carboxyl group, a carboxylate salt, a sulfonic acid group, a sulfonate salt, and a mixture thereof 1 Independently selected from alkyl groups having from 12 to 12 carbon atoms, wherein the second active ingredient is effective to substantially inhibit exoprotein production from Gram-positive bacteria The absorbent exoprotein-suppressing article according to claim 1.   The second active ingredient is selected from the group consisting of sodium lauryl sarcosinate, lauryl amide MEA, lauryl amide DEA, lauryl amide propyldimethylamine, disodium lauryl amide MEA sulfosuccinate, and disodium lauroamphodiacetate. The absorbent exoprotein-suppressing article according to claim 17,   18. The absorbent exoprotein-suppressing article of claim 17, wherein the second active ingredient is present in an amount of at least about 0.0001 millimoles per gram of absorbent article.   The absorptive exoprotein-suppressing article according to claim 17, wherein the second active ingredient is effective to substantially suppress TSST-1 production from Staphylococcus aureus.   The absorbent article comprises a menstrual tampon, sanitary napkin, panty liner, incontinence underwear, diaper, wound dressing, dental thrombus, medical thrombus, surgical thrombus, and nasal thrombus The absorbent exoprotein-suppressing article according to claim 17, which is selected from the group consisting of: General formula, i.e.

And wherein R ²⁰ is an alkyl group having from about 8 to about 18 carbon atoms, R ²¹ and R ²² are hydrogen, 1 to about 18 Independently selected from the group consisting of alkyl groups with up to carbon atoms, which have one or more substituted moieties selected from the group consisting of hydroxyl groups, carboxyl groups, carboxyl salts, and imidazolines The absorbent exoprotein-suppressing article according to claim 1, wherein the second active ingredient is effective to substantially suppress exoprotein production from Gram-positive bacteria. Wherein R ²² is lauryl amine, lauryl aminopropionic acid, sodium lauryl amino dipropionate acid, lauryl hydroxyethyl imidazoline, and according to claim 22, characterized in that it comprises a selected amine from mixtures thereof Absorbent exoprotein suppression article.   23. The absorbent exoprotein-suppressing article of claim 22, wherein the second active ingredient is present in an amount of at least about 0.0001 millimoles per gram of absorbent article.   The absorbent article comprises a menstrual tampon, sanitary napkin, panty liner, incontinence underwear, diaper, wound dressing, dental thrombus, medical thrombus, surgical thrombus, and nasal thrombus The absorbent exoprotein-suppressing article according to claim 22, wherein the article is selected from the group consisting of: General formula, ie

And wherein R ²³ is an alkyl group having from about 8 to about 18 carbon atoms, R ²⁴ , R ²⁵ and R ²⁶ are hydrogen, 1 And one or more substituted moieties selected from the group consisting of hydroxyl groups, carboxyl groups, carboxyl salts, and imidazolines. The absorbable exoprotein inhibitor of claim 1, wherein the second active ingredient is effective to substantially inhibit exoprotein production from Gram-positive bacteria. Goods.   27. The absorbent exoprotein-suppressing article according to claim 26, wherein the second active ingredient is TEA laureth sulfate.   27. The absorbent exoprotein-suppressing article of claim 26, wherein the second active ingredient is present in an amount of at least about 0.0001 millimoles per gram of absorbent article.   27. The absorbent exoprotein-suppressing article according to claim 26, wherein the second active ingredient is effective to substantially suppress TSST-1 production from Staphylococcus aureus.   The absorbent article comprises a menstrual tampon, sanitary napkin, panty liner, incontinence underwear, diaper, wound dressing, dental thrombus, medical thrombus, surgical thrombus, and nasal thrombus 27. The absorbent exoprotein-suppressing article according to claim 26, characterized in that it is selected from: An exoprotein inhibitor used in the vagina to suppress exoprotein production from Gram-positive bacteria and comprising a non-absorbable substrate on which an effective amount of the first active ingredient is deposited, wherein the first active ingredient is , The general formula, ie

Wherein R ¹ is H,

^{-OR 5, -R 6 C (O} ) H, -R 6 OH, -R 6 COOH, -OR 6 OH, -OR 6 COOH, -C (O) NH 2,

And NH ₂ and their salts, R ⁵ is a monovalent saturated or unsaturated aliphatic hydrocarbyl moiety, R ⁶ is a divalent saturated or unsaturated aliphatic hydrocarbyl moiety, R ⁷ is a trivalent saturated or unsaturated aliphatic hydrocarbyl moiety, R ⁸ is a monovalent substituted or unsubstituted saturated or unsaturated aliphatic hydrocarbyl moiety, which may or may not be intervened by heteroatoms, ² , R ³ and R ⁴ are independently selected from the group consisting of H, OH, COOH, and —C (O) R ⁹ , wherein R ⁹ is hydrogen or a monovalent saturated or unsaturated aliphatic hydrocarbyl moiety; The exoprotein inhibitor, wherein the first active ingredient is effective in suppressing exoprotein production from Gram-positive bacteria.   2-phenylethanol, benzyl alcohol, trans-cinnamic acid, 4-hydroxybenzoic acid, methyl ester, 2-hydroxybenzoic acid, 2-hydroxybenzamide, acetyltyrosine, 3,4,5-trihydroxybenzoic acid, lauryl 3, 32. The exoprotein of claim 31 selected from the group consisting of 4,5-trihydroxybenzoate, phenoxyethanol, 4-hydroxy-3-methoxybenzoic acid, p-aminobenzoic acid, and acetaminophen. Suppressor.   32. The exoprotein inhibitor of claim 31, wherein the first active ingredient is present in an amount of at least about 0.01 micromole per gram of non-absorbent article.   32. The exoprotein inhibitor according to claim 31, wherein the first active ingredient is effective to substantially suppress TSST-1 production from Staphylococcus aureus.   32. The exoprotein suppression of claim 31, wherein the non-absorbable article is selected from the group consisting of a non-absorbable incontinence device, a contraceptive barrier device, a contraceptive sponge, a tampon applicator, or an irrigator. body. Ether connecting the C ₈ -C ₁₈ fatty aliphatic alcohol, an ester, amide, further comprising glycosides, or a second active ingredient an effective amount with an amine linkage, the second active ingredient, exo from Gram-positive bacteria The exoprotein inhibitor according to claim 31, which is effective for substantially suppressing protein production. General formula, i.e.
R ¹⁰ —O—R ¹¹
And wherein R ¹⁰ is a linear or branched alkyl having from 8 to about 18 carbon atoms, or a linear or branched alkenyl, and R ¹¹ is , Alcohol, polyalkoxylated sulfate, and polyalkoxylated sulfosuccinate, wherein the second active ingredient is effective to substantially inhibit exoprotein production from Gram-positive bacteria The exoprotein inhibitor according to claim 31, wherein   The second active ingredient is laureth-3, laureth-4, laureth-5, PPG-5 lauryl ether, 1-0-dodecyl-rac-glycerol, sodium laureth sulfate, potassium laureth sulfate, laureth (3) disulfosuccinate 38. The exoprotein inhibitor according to claim 37, selected from the group consisting of sodium, laureth (3) dipotassium sulfosuccinate, and polyethylene oxide (2) sorbitol ether.   38. The exoprotein inhibitor of claim 37, wherein the second active ingredient is present in an amount of at least about 0.0001 micromole per gram of non-absorbent article.   The exoprotein inhibitor according to claim 37, wherein the second active ingredient is effective to substantially suppress TSST-1 production from Staphylococcus aureus.   38. The exoprotein suppression of claim 37, wherein the non-absorbable article is selected from the group consisting of a non-absorbable incontinence device, a contraceptive barrier device, a contraceptive sponge, a tampon applicator, or an irrigator. body.   32. The exoprotein inhibitor according to claim 31, further comprising an effective amount of a second active ingredient comprising an alkyl polyglycoside effective to substantially suppress exoprotein production from Gram-positive bacteria.   43. The exoprotein suppression of claim 42, wherein the non-absorbable article is selected from the group consisting of a non-absorbable incontinence device, a contraceptive barrier device, a contraceptive sponge, a tampon applicator, and an irrigator. body.   43. The exoprotein inhibitor of claim 42, wherein the second active ingredient is present in an amount of at least about 0.0001 micromole per gram of non-absorbent article.   43. The exoprotein inhibitor according to claim 42, wherein the alkyl polyglycoside is selected from Glucopon220, Glucopon225, Glucopon425, Glucopon600, Glucopon625, and TL2141.   And further comprising an effective amount of a second active ingredient selected from the group consisting of glycerol monolaurate and milles-3-myristate, said active ingredient substantially inhibiting exoprotein production from Gram-positive bacteria. 32. The exoprotein inhibitor according to claim 31, which is effective. General formula, i.e.

Further comprising an effective amount of a second active ingredient, wherein R ¹⁷ containing a carbonyl carbon is an alkyl group having 8 to 18 carbon atoms, and R ¹⁸ and R ¹⁹ are hydrogen, or 1 which may or may not be substituted with a functional group selected from ester, ether, amine, hydroxyl, carboxyl, carboxylate, sulfonate, sulfonate, and mixtures thereof Independently selected from alkyl groups having up to 12 carbon atoms, wherein the second active ingredient is effective to substantially suppress exoprotein production from Gram-positive bacteria. Item 32. The exoprotein inhibitor according to Item 31.   The second active ingredient is selected from the group consisting of sodium lauryl sarcosinate, lauryl amide monoethanolamide, lauryl amide diethanolamide, lauryl amide propyl dimethylamine, lauryl amide monoethanolamide sulfosuccinate disodium, and lauroamphodiacetate disodium. 48. The exoprotein inhibitor according to claim 47, which is selected.   48. The exoprotein inhibitor of claim 47, wherein the second active ingredient is present in an amount of at least about 0.0001 millimoles per gram of absorbent article.   48. The exoprotein inhibitor according to claim 47, wherein the second active ingredient is effective to substantially suppress TSST-1 production from Staphylococcus aureus.   48. The exoprotein suppression of claim 47, wherein the nonabsorbable article is selected from the group consisting of a nonabsorbable incontinence device, a contraceptive barrier device, a contraceptive sponge, a tampon applicator, and an irrigator. body. General formula, i.e.

And wherein R ²⁰ is an alkyl group having from about 8 to about 18 carbon atoms, R ²¹ and R ²² are hydrogen, 1 to about 18 Independently selected from the group consisting of alkyl groups with up to carbon atoms, which have one or more substituted moieties selected from the group consisting of hydroxyl groups, carboxyl groups, carboxyl salts, and imidazolines 32. The exoprotein suppressor according to claim 31, wherein the second active ingredient is effective to substantially suppress exoprotein production from Gram-positive bacteria. Wherein R ²² is lauryl amine, lauryl aminopropionic acid, sodium lauryl amino dipropionate acid, lauryl hydroxyethyl imidazoline, and according to claim 52, characterized in that it comprises a selected amine from mixtures thereof Exoprotein inhibitor.   53. The exoprotein inhibitor of claim 52, wherein the second active ingredient is present in an amount of at least about 0.0001 millimoles per gram of absorbent article.   53. The exoprotein suppression of claim 52, wherein the non-absorbable article is selected from the group consisting of a non-absorbable incontinence device, a contraceptive barrier device, a contraceptive sponge, a tampon applicator, or an irrigator. body. General formula, i.e.

And wherein R ²³ is an alkyl group having from about 8 to about 18 carbon atoms, R ²⁴ , R ²⁵ and R ²⁶ are hydrogen, 1 And one or more substituted moieties selected from the group consisting of hydroxyl groups, carboxyl groups, carboxyl salts, and imidazolines. 32. The exoprotein inhibitor according to claim 31, wherein the second active ingredient is effective to substantially suppress exoprotein production from Gram-positive bacteria.   57. The exoprotein inhibitor according to claim 56, wherein the second active ingredient is triethanolamide laureth sulfate.   57. The exoprotein inhibitor of claim 56, wherein the second active ingredient is present in an amount of at least about 0.0001 millimoles per gram of non-absorbent article.   57. The exoprotein inhibitor according to claim 56, wherein the second active ingredient is effective to substantially suppress TSST-1 production from Staphylococcus aureus.   57. The exoprotein suppression of claim 56, wherein the non-absorbable article is selected from the group consisting of a non-absorbable incontinence device, a contraceptive barrier device, a contraceptive sponge, a tampon applicator, or an irrigator. body. A vaginal cleansing composition for inhibiting exoprotein production from gram positive bacteria in and around the vagina, comprising a pharmaceutically acceptable carrier and an effective amount of a first active ingredient, wherein the first The active ingredient has the general formula:

Wherein R ¹ is H,

^{-OR 5, -R 6 C (O} ) H, -R 6 OH, -R 6 COOH, -OR 6 OH, -OR 6 COOH, -C (O) NH 2,

And NH ₂ and their salts, R ⁵ is a monovalent saturated or unsaturated aliphatic hydrocarbyl moiety, R ⁶ is a divalent saturated or unsaturated aliphatic hydrocarbyl moiety, R ⁷ is a trivalent saturated or unsaturated aliphatic hydrocarbyl moiety, R ⁸ is a monovalent substituted or unsubstituted saturated or unsaturated aliphatic hydrocarbyl moiety, which may or may not be intervened by heteroatoms, ² , R ³ and R ⁴ are independently selected from the group consisting of H, OH, COOH, and —C (O) R ⁹ , wherein R ⁹ is hydrogen or a monovalent saturated or unsaturated aliphatic hydrocarbyl moiety; The vaginal cleaning composition is characterized in that the first active ingredient is effective in suppressing exoprotein production from Gram-positive bacteria.   The first active ingredient is 2-phenylethanol, benzyl alcohol, trans-cinnamic acid, 4-hydroxybenzoic acid, methyl ester, 2-hydroxybenzoic acid, 2-hydroxybenzamide, acetyltyrosine, 3,4,5-tri 62. The composition of claim 61, comprising hydroxybenzoic acid, lauryl 3,4,5-trihydroxybenzoate, phenoxyethanol, 4-hydroxy-3-methoxybenzoic acid, p-aminobenzoic acid, and acetaminophen. Vaginal cleansing composition.   62. The vaginal cleansing composition of claim 61, further comprising about 0.2 millimoles / liter to about 50 millimoles / liter of aromatic compound.   62. The vaginal cleansing composition of claim 61, wherein the first active ingredient is effective to substantially inhibit TSST-1 production from Staphylococcus aureus. Ether connecting the C ₈ -C ₁₈ fatty aliphatic alcohol, an ester, amide, further comprising glycosides, or a second active ingredient an effective amount with an amine linkage, the second active ingredient, exo from Gram-positive bacteria 62. The vaginal cleansing composition of claim 61, which is effective to substantially inhibit protein production. General formula, i.e.
R ¹⁰ —O—R ¹¹
And wherein R ¹⁰ is a linear or branched alkyl having from 8 to about 18 carbon atoms, or a linear or branched alkenyl, and R ¹¹ is , Alcohol, polyalkoxylated sulfate, and polyalkoxylated sulfosuccinate, wherein the second active ingredient is effective to substantially inhibit exoprotein production from Gram-positive bacteria 62. A vaginal cleansing composition according to claim 61.   The second active ingredient is laureth-3, laureth-4, laureth-5, PPG-5 lauryl ether, 1-0-dodecyl-rac-glycerol, sodium laureth sulfate, potassium laureth sulfate, laureth (3) disulfosuccinate 67. The vaginal cleansing composition of claim 66, selected from the group consisting of sodium, laureth (3) dipotassium sulfosuccinate, and polyethylene oxide (2) sorbitol ether.   68. The vaginal cleansing composition of claim 66, further comprising from about 0.25 millimoles / liter to about 10 millimoles / liter of the second active ingredient.   68. The vaginal cleansing composition of claim 66, wherein the second active ingredient is effective to substantially inhibit TSST-1 production from S. aureus.   62. The vaginal cleansing composition of claim 61, further comprising an effective amount of a second active ingredient comprising an alkyl polyglycoside effective to substantially inhibit exoprotein production from Gram positive bacteria. The alkyl polyglycoside has the general formula:
H- (Zn) -O-R ¹⁴
Wherein Z is a sugar residue having 5 or 6 carbon atoms, n is an integer from 1 to 6, and R ¹⁴ is a straight chain having from about 8 to about 18 carbon atoms. The vaginal cleansing composition according to claim 70, wherein the composition is a chain alkyl group.   71. The vaginal cleansing composition of claim 70, further comprising from about 0.25 millimoles / liter to about 5 millimoles / liter of alkyl polyglycoside.   71. The vaginal cleansing composition of claim 70, wherein the alkyl polyglycoside is selected from Glucopon220, Glucopon225, Glucopon425, Glucopon600, Glucopon625, and TL2141.   And further comprising an effective amount of a second active ingredient selected from the group consisting of glycerol monolaurate and milles-3-myristate, said active ingredient substantially inhibiting exoprotein production from Gram-positive bacteria. 62. The vaginal cleansing composition of claim 61, wherein the composition is effective. General formula, i.e.

Further comprising an effective amount of a second active ingredient, wherein R ¹⁷ containing a carbonyl carbon is an alkyl group having 8 to 18 carbon atoms, and R ¹⁸ and R ¹⁹ are hydrogen, or 1 which may or may not be substituted with a functional group selected from ester, ether, amine, hydroxyl, carboxyl, carboxylate, sulfonate, sulfonate, and mixtures thereof Independently selected from alkyl groups having up to 12 carbon atoms, wherein the second active ingredient is effective to substantially suppress exoprotein production from Gram-positive bacteria. Item 62. The vaginal cleaning composition according to Item 61.   The second active ingredient is selected from the group consisting of sodium lauryl sarcosinate, lauryl amide monoethanolamide, lauryl amide diethanolamide, lauryl amide propyl dimethylamine, lauryl amide monoethanolamide sulfosuccinate disodium, and lauroamphodiacetate disodium. 78. The vaginal cleansing composition of claim 75, wherein the composition is selected.   78. The vaginal cleansing composition of claim 75, further comprising from about 0.25 millimoles / liter to about 5 millimoles / liter of the second active ingredient.   The vaginal cleansing composition of claim 75, wherein the second active ingredient is effective to substantially inhibit TSST-1 production from Staphylococcus aureus. General formula, ie

And wherein R ²⁰ is an alkyl group having from about 8 to about 18 carbon atoms, R ²¹ and R ²² are hydrogen, 1 to about 18 Independently selected from the group consisting of alkyl groups with up to carbon atoms, which have one or more substituted moieties selected from the group consisting of hydroxyl groups, carboxyl groups, carboxyl salts, and imidazolines 62. The vaginal cleansing composition of claim 61, wherein the second active ingredient is effective to substantially inhibit exoprotein production from Gram positive bacteria.   80. The vaginal cleansing composition of claim 79, further comprising from about 0.25 millimoles / liter to about 5 millimoles / liter of the second active ingredient.   80. The vaginal cleansing composition of claim 79, wherein the second active ingredient is effective to substantially inhibit TSST-1 production from Staphylococcus aureus. General formula, i.e.

And wherein R ²³ is an alkyl group having from about 8 to about 18 carbon atoms, R ²⁴ , R ²⁵ and R ²⁶ are hydrogen, 1 And one or more substituted moieties selected from the group consisting of hydroxyl groups, carboxyl groups, carboxyl salts, and imidazolines. 62. The vaginal cleansing composition of claim 61, wherein the second active ingredient is effective to substantially inhibit exoprotein production from Gram positive bacteria.   83. The vaginal cleansing composition of claim 82, wherein the second active ingredient is triethanolamide laureth sulfate.   83. The vaginal cleansing composition of claim 82, further comprising from about 0.25 millimoles / liter to about 5 millimoles / liter of the second active ingredient.   83. The vaginal cleansing composition of claim 82, wherein the second active ingredient is effective to substantially inhibit TSST-1 production from Staphylococcus aureus. A method of inhibiting exoprotein production from Gram positive bacteria, comprising exposing the Gram positive bacteria to an effective amount of a first active ingredient, wherein the first active ingredient has the general formula:

Wherein R ¹ is H,

^{-OR 5, -R 6 C (O} ) H, -R 6 OH, -R 6 COOH, -OR 6 OH, -OR 6 COOH, -C (O) NH 2,

And a method selected from the group consisting of NH ₂ and salts thereof.